Fig. 1.
HAD definitions and HAD patient disposition: a primary and alternative definitions of HAD used in this post hoc analysis; b CARE-MS I and II alemtuzumab-treated HAD patient disposition through year 9 defined by the primary HAD definition. CARE-MS Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, DMT disease-modifying therapy, Gd gadolinium, HAD highly active disease, MRI magnetic resonance imaging, SC IFNB-1a subcutaneous interferon-β-1a